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donor body size measurements (height, weight, body surface area),
or between days required for collection and recipient body size
measurements. There was a statistically signiﬁcant association be-
tween product characteristics (CD34 cell dose, CFU-GM, MNC
cell dose) and number of collection days (P  .01 for CD34, P 
.001 for CFU-GM, and P  .0001 for MNC). For CD34 cell
dose ( 106/kg) the median number of cells collected was 6.56
(range, 3.1–21.1) for 1 day collection, 7.3 (range, 3.0–24.9) for 2
days collection, and 3.2 (range, 1.8–5.9) for  2 days collection.
The number of collections was not signiﬁcantly related to engraft-
ment in univariate analysis. However, after adjustment for CD34
dose infused (using Cox regression), the number of collection days
was signiﬁcantly related to platelet engraftment (P  .05), but not
to neutrophil engraftment (P  .17) or red cell engraftment (P 
.94). We conclude that all donors were able to mobilize sufﬁcient
cells for engraftment, but that grafts requiring  2 collections are
associated with a delay in platement engraftment after correction
for CD34 cell dose.
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PREDICTIVE FACTORS FOR ADEQUATE HEMATOPOIETIC STEM CELL
MOBILIZATION WITH HEMATOPOIETIC GROWTH FACTOR ALONE IN
PATIENTS WITH LYMPHOMA
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Burns, L., Kaufman, D., McGlave, P., Miller, J., Slungaard, A.,
Weisdorf, D. University of Minnesota Division of Hematology, Oncology,
and Transplantation, Minneapolis, MN.
There are no deﬁned factors to reliably predict which patients
will mobilize sufﬁcient progenitor cells with hematopoietic growth
factor (HGF) alone. Furthermore, it is unclear whether HGF
mobilization impedes subsequent chemotherapy mobilization. To
address this question, we prospectively evaluated 175 patients with
lymphoma enrolled from January 1996 to August 2004. All patients
were mobilized with G-CSF (250 g/m2/day), followed by a sec-
ond mobilization with chemotherapy (cyclophosphamide, mitox-
antrone, cytarabine) and G-CSF (250 g/m2/day). Using HGF
alone, 58 patients (33%) patients collected  2  106 CD34
cells/kg, whereas 90 patients (51%) collected  2  106 CD34
cells/kg with only chemotherapy mobilization. Sixty-four patients
(37%) collected 2 106 CD34 cells/kg after mobilization with
either HGF or chemotherapy. Of these poor mobilizers, 41 (64%)
had combined collections totalling  2  106 CD34 cells/kg.
The median number of collections in each group was 3 (HGF, 2–4;
chemotherapy, 1–8). The median yield of PBSC collected with
HGF alone was 58% of that obtained with chemotherapy mobili-
zation (1.37  106 CD34 cells/kg [0.12–10.1] vs 2.37  106
CD34 cells/kg [0.0–100.7]; P  .0001). Some 55% of patients
had better mobilization with chemotherapy than with HGF, and
another 15% had equivalent collections ( 0.5  106 CD34
cells/kg). Variables analyzed included age, disease type, stage at
diagnosis, numbers and cycles of previous chemotherapy regimens,
presence of bone marrow involvement at any time, previous radi-
ation, and length of time from diagnosis to the ﬁrst day of HGF
harvest. In univariate analysis, patients with stage IV disease at
diagnosis (odds ratio [OR] 0.5 [0.24–1.02]; P .06) and a longer
interval between diagnosis and harvest (OR  0.85 [0.71–1.01];
P  .06) had a lower likelihood of adequate collection when
mobilized with HGF alone. When evaluating only the patients
who collected  2  106 CD34 cells/kg by either method,
multivariate analysis demonstrated that stage IV disease and within
the subset of patients with Hodgkin’s lymphoma, older age and a
longer interval to harvest predicted a poorer collection with HGF
alone. There is no evidence that the use of HGF mobilization
hinders the ability to later collect PBSC with chemotherapy mo-
bilization. Based on these data, and to spare potential toxicity and
expense of chemotherapy mobilization, it may be reasonable to
attempt HGF mobilization in lymphoma patients with earlier-
stage disease or a shorter time from diagnosis to harvest.
Table 1. Multivariate Analysis Predicting Patients that are Poor
Mobilizers with HGF Alone*
OR (95% CI) p-Value
Stage of Disease
Stage I–III —
Stage IV 0.30 (0.11–0.80) p < 0.02
Patients with Hodgkin
Lymphoma (n  57)
Increasing Age (10 year
increments) 0.23 (0.06–0.90) p < 0.04
Increasing Interval from
Diagnosis to Harvest
(12 month increments) 0.18 (0.03–0.91) p < 0.04
*Includes only patients collecting 2  106 with either HGF or
chemotherapy mobilization.
204
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Almost all of the hematopoietic progenitor cells that durably
reconstitute NOD/SCID mice and the majority of long-term and
short-term multilineage colony initiating cells in fresh human
umbilical cord blood (UCB) can be isolated by ﬂow-sorting
low-side scatter cells that express high levels of the enzyme
aldehyde dehydrogenase (ALDHbrSSClo). Such highly enriched
ALDHbrSSClo cell populations may be useful in expansion of UCB
stem cells and other clinical applications. These clinical prepara-
tions of UCB stem cells are likely to be derived from UCB that has
been frozen, banked, and then thawed to manufacture a therapeutic
preparation. We explored ways to prepare thawed UCB for ﬂow
sorting using ALDESORT and other markers. Frozen UCB units
banked using the COBLT method and designated for research
use under approved institutional protocols were thawed and
washed in dextran/albumin. Several protocols were explored for
removing RBCs without signiﬁcantly reducing the number of
ALDHbrSSClo. Successful immunomagnetic depletion of RBCs
was achieved with antiglycophorin A, clone 2B7 (anti-GlyA) and of
monocyte lineage cells with anti-CD14, clone BA-8 using EasySep
(TM, StemCell Technologies, Inc.). Treatment of thawed, washed
UCB preparations (n  36) with this method removed 99.5% of
the RBCs and 73% of the mononuclear cells, and permitted re-
covery of 77% of the ALDHbrSSClo cells, for a net 3.2-fold
enrichment of the ALDHbrSSClo population. The resulting RBC/
nucleated cell ratio in the depleted preparations was  2; these
preparations could be used with ALDESORT for subsequent ﬂow
sorting. After depletion with anti-GlyA and anti-CD14, no mea-
surable residual iron from the EasySep reagent and very low levels
of mouse immunoglobulin were detected in the cell preparation
before sorting. The method did not damage cells, because  99%
of the cells in the cell preparation excluded 7-aminoactinomycin D.
Hematopoietic colony-forming cells were enriched 6-fold pre-
EasySep to post-EasySep depletion. Flow-sorted ALDHbrSSClo
populations prepared using anti-GlyA and anti-CD14 with
EasySep were enriched 39-fold for 14-day hematopoietic colony-
forming cells relative to whole thawed cords and have been used
successfully in ex vivo expansion protocols. Collectively, these
results suggest that this method could be developed to manufacture
cell preparations from banked, thawed UCB that will prove suit-
able for clinical use.
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